MedTrace Logo

The Efficacy of the Alma Hybrid System for a New Approach of Facial Skin Treatment

NCT04640207 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-07-22

No results posted yet for this study

Summary

The study is aimed to evaluate the efficacy of the Alma Hybrid system for a new approach of facial skin treatment, using both ablative and non-ablative wavelengths.

The study will include 20 subjects with mild-moderate photodamaged skin, that will undergo 2 facial skin treatments. Follow up visit to evaluate the efficacy of the treatments will take place 1 and 3 months after the last treatment.

Conditions

  • Rejuvenation

Interventions

DEVICE

Facial skin treatment

Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths

Sponsors & Collaborators

  • Alma Lasers

    lead INDUSTRY

Principal Investigators

  • Thomas Griffin, MD · Dermatology Associates of Plymouth Meeting, P.C.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2021-07-18
Completion
2021-07-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640207 on ClinicalTrials.gov